132 related articles for article (PubMed ID: 25826034)
41. [Treatment of systemic scleroderma: update].
Allanore Y; Kahan A
Ann Dermatol Venereol; 2006 Mar; 133(3):286-91. PubMed ID: 16800188
[No Abstract] [Full Text] [Related]
42. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
[TBL] [Abstract][Full Text] [Related]
43. Systemic scleroderma-related interstitial pneumonia associated with borderline pulmonary arterial hypertension.
Sugino K; Kabuki T; Shibuya K; Homma S
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29804068
[TBL] [Abstract][Full Text] [Related]
44. Screening for pulmonary arterial hypertension in systemic sclerosis.
Busteed S; Moots RJ; Thompson RN
Rheumatology (Oxford); 2004 Oct; 43(10):1315-6; author reply 1316. PubMed ID: 15448224
[No Abstract] [Full Text] [Related]
45. [Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment].
Zuber JP; Chizzolini C; Leimgruber A; Bart PA; Spertini F
Rev Med Suisse; 2006 Apr; 2(62):1058, 1060-6. PubMed ID: 16711151
[TBL] [Abstract][Full Text] [Related]
46. Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis.
Distler JH; Hoeper MM; Distler O
Nat Clin Pract Rheumatol; 2008 Mar; 4(3):160-4. PubMed ID: 18212761
[TBL] [Abstract][Full Text] [Related]
47. Riociguat for pulmonary hypertension.
Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
[TBL] [Abstract][Full Text] [Related]
48. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
[TBL] [Abstract][Full Text] [Related]
49. Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?
Black C
Rheumatology (Oxford); 2005 Feb; 44(2):141-2. PubMed ID: 15681336
[No Abstract] [Full Text] [Related]
50. [Vasodilator agents in pulmonary artery hypertension of systemic scleroderma].
Phlippoteau C; Brenot F; Blétry O; Simmonneau G; Duroux P
Rev Mal Respir; 1990; 7(3):249-54. PubMed ID: 2114030
[TBL] [Abstract][Full Text] [Related]
51. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis.
Distler O; Behrens F; Huscher D; Foeldvari I; Zink A; Nash P; Denton CP; Humbert M; Matucci-Cerinic M; Seibold J; Rubin L; Furst DE
Rheumatology (Oxford); 2006 Dec; 45(12):1455-7. PubMed ID: 16920751
[No Abstract] [Full Text] [Related]
52. Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis?
Steen VD; Champion H
Int J Clin Pract Suppl; 2011 Jan; (169):1-3. PubMed ID: 21176008
[No Abstract] [Full Text] [Related]
53. [Future aspects of the treatment of pulmonary arterial hypertension].
Ghofrani HA; Rosenkranz S; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S338-40. PubMed ID: 17139602
[TBL] [Abstract][Full Text] [Related]
54. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
[TBL] [Abstract][Full Text] [Related]
55. The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension.
Mukerjee D; Yap LB; Ong V; Denton CP; Howells K; Black CM; Coghlan JG
Ann Rheum Dis; 2004 Dec; 63(12):1627-31. PubMed ID: 15547087
[TBL] [Abstract][Full Text] [Related]
56. Dyspnea due to pulmonary hypertension and interstitial lung disease in scleroderma: room for improvement in diagnosis and management.
Racz H; Mehta S
J Rheumatol; 2006 Sep; 33(9):1723-5. PubMed ID: 16960934
[No Abstract] [Full Text] [Related]
57. Pulmonary hypertension associated with connective tissue disease.
Fagan KA; Badesch DB
Prog Cardiovasc Dis; 2002; 45(3):225-34. PubMed ID: 12525998
[TBL] [Abstract][Full Text] [Related]
58. Clinical research in pulmonary hypertension comes of age.
Barberà JA
Arch Bronconeumol; 2014 Nov; 50(11):463-4. PubMed ID: 24998025
[No Abstract] [Full Text] [Related]
59. Macitentan and pulmonary arterial hypertension.
Macchia A; Mariani J; Tognoni G
N Engl J Med; 2014 Jan; 370(1):82. PubMed ID: 24382074
[No Abstract] [Full Text] [Related]
60. Macitentan and pulmonary arterial hypertension.
Tonelli AR; Dweik RA
N Engl J Med; 2014 Jan; 370(1):81-2. PubMed ID: 24382073
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
